RU2011104059A - Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид - Google Patents

Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид Download PDF

Info

Publication number
RU2011104059A
RU2011104059A RU2011104059/15A RU2011104059A RU2011104059A RU 2011104059 A RU2011104059 A RU 2011104059A RU 2011104059/15 A RU2011104059/15 A RU 2011104059/15A RU 2011104059 A RU2011104059 A RU 2011104059A RU 2011104059 A RU2011104059 A RU 2011104059A
Authority
RU
Russia
Prior art keywords
corticosteroid
composition
dose
use according
suspension
Prior art date
Application number
RU2011104059/15A
Other languages
English (en)
Inventor
Джеймс Д. ПИПКИН (US)
Джеймс Д. Пипкин
Руперт О. ЦИММЕРЕР (US)
Руперт О. ЦИММЕРЕР
Дайан О. ТОМПСОН (US)
Дайан О. ТОМПСОН
Джерольд Л. МОШЕР (US)
Джерольд Л. МОШЕР
Original Assignee
Сайдекс Фармасьютикалз, Инк. (Us)
Сайдекс Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайдекс Фармасьютикалз, Инк. (Us), Сайдекс Фармасьютикалз, Инк. filed Critical Сайдекс Фармасьютикалз, Инк. (Us)
Publication of RU2011104059A publication Critical patent/RU2011104059A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Применение водной жидкой композиции, содержащей водный жидкий носитель, сульфоалкиловый эфир циклодекстрина и дозу растворенного кортикостероида, для изготовления лекарственного средства, для лечения заболевания или нарушения дыхательных путей у нуждающегося в этом субъекта, где указанную композицию вводят субъекту ингаляцией, при этом данная композиция обеспечивает улучшенный фармакокинетический профиль по сравнению с композицией на основе суспензии, введенной в аналогичных условиях. ! 2. Система, включающая распылитель, оснащенный резервуаром, и водную жидкую композицию, содержащую водный жидкий носитель, усилитель растворимости и дозу кортикостероида, в которой во время распыления композиции распылитель обеспечивает процентное уменьшение скорости увеличения концентрации кортикостероида в композиции, находящейся в резервуаре, по сравнению со скоростью увеличения концентрации композиции на основе суспензии, распыляемой распылителем в аналогичных условиях. ! 3. Применение по п.1, в котором доза кортикостероида присутствует в количестве, достаточном для достижения в плазме среднего значения AUCt, равного 160-1600 пг·ч/мл, и молярное отношение SAE-CD к кортикостероиду больше 10:1. ! 4. Применение по п.1, в котором композиция содержит 25-400 мкг кортикостероида и обеспечивает достижение в плазме значения AUCt, равного 150-1600 пг·ч/мл для кортикостероида. ! 5. Применение по п.1, в котором композиция содержит по меньшей мере 25 мкг кортикостероида и обеспечивает достижение в плазме значения AUCt, нормализованного в отношении дозы кортикостероида, равного по меньшей мере 6 (пг·ч/мл)/мкг кортикостероида. ! 6. Применение по п.1, в

Claims (20)

1. Применение водной жидкой композиции, содержащей водный жидкий носитель, сульфоалкиловый эфир циклодекстрина и дозу растворенного кортикостероида, для изготовления лекарственного средства, для лечения заболевания или нарушения дыхательных путей у нуждающегося в этом субъекта, где указанную композицию вводят субъекту ингаляцией, при этом данная композиция обеспечивает улучшенный фармакокинетический профиль по сравнению с композицией на основе суспензии, введенной в аналогичных условиях.
2. Система, включающая распылитель, оснащенный резервуаром, и водную жидкую композицию, содержащую водный жидкий носитель, усилитель растворимости и дозу кортикостероида, в которой во время распыления композиции распылитель обеспечивает процентное уменьшение скорости увеличения концентрации кортикостероида в композиции, находящейся в резервуаре, по сравнению со скоростью увеличения концентрации композиции на основе суспензии, распыляемой распылителем в аналогичных условиях.
3. Применение по п.1, в котором доза кортикостероида присутствует в количестве, достаточном для достижения в плазме среднего значения AUCt, равного 160-1600 пг·ч/мл, и молярное отношение SAE-CD к кортикостероиду больше 10:1.
4. Применение по п.1, в котором композиция содержит 25-400 мкг кортикостероида и обеспечивает достижение в плазме значения AUCt, равного 150-1600 пг·ч/мл для кортикостероида.
5. Применение по п.1, в котором композиция содержит по меньшей мере 25 мкг кортикостероида и обеспечивает достижение в плазме значения AUCt, нормализованного в отношении дозы кортикостероида, равного по меньшей мере 6 (пг·ч/мл)/мкг кортикостероида.
6. Применение по п.1, в котором композиция содержит по меньшей мере 25 мкг кортикостероида и обеспечивает достижение в плазме значения AUCt, нормализованного в отношении дозы кортикостероида, равного по меньшей мере 8 (пг·ч/мл)/мкг кортикостероида.
7. Применение по любому из пп.1 или 3-6, в котором циклодекстрин является соединением формулы I:
Figure 00000001
где n означает 4, 5 или 6;
R1, R2, R3, R4, R5, R6, R7, R8 и R9 каждый независимо означают -О- или группу -O-(С2-С6 алкилен)-SO3 -, причем по меньшей мере один из R1-R9 независимо означает группу -О-(С2-С6 алкилен)-SO3 -, группу -О-(CH2)mSО3 -, где m равно 2-6, -ОСН2СH2СН2SО3 - или -ОСН2СН2СН2СН2SO3 -; и
S1, S2, S3, S4, S5, S6, S7, S8 и S9 каждый независимо означают фармацевтически приемлемый катион.
8. Применение по любому из пп.1 или 3-6, в котором циклодекстрин является соединением формулы II (SAEх-α-CD), где "х" равно 1-18; формулы III (SAEy-β-CD), где "y" равно 1-21; или формулы IV (SAEz-γ-CD), где "z" равно 1-24, "SAE" означает заместитель, являющийся сульфоалкиловым эфиром, и величины "х", "y" и "z" означают среднюю степень замещения в виде числа групп сульфоалкилового эфира в одной молекуле CD.
9. Применение по п.1, в котором значение Сmax, полученное для композиции, содержащей кортикостероид, по меньшей мере в 1,5 раза больше значения Сmax, полученного для композиции на основе суспензии, когда доза кортикостероида в композиции примерно в 2 раза меньше дозы в суспензии.
10. Применение по п.1, в котором композиция обеспечивает достижение значения Сmax (пг/мл), равного 1600-1800, на основе данных, ненормализованных в отношении дозы.
11. Применение по п.1, в котором на основе нормализованной номинальной дозы кортикостероида значение Сmax, полученное для композиции, содержащей кортикостероид, по меньшей мере в 1,7 раза больше значения Сmax, полученного для композиции на основе суспензии, когда доза кортикостероида в композиции и суспензии является примерно одинаковой.
12. Применение по п.1, в котором композиция обеспечивает достижение значения AUCinf (пг·ч/мл), равного 250-2500, на основе данных, ненормализованных в отношении дозы.
13. Применение по п.1, в котором на основе ненормализованной дозы кортикостероида значение AUCinf, полученное для композиции, содержащей кортикостероид, в 1,5-3,5 раза больше значения AUCinf, полученного для композиции на основе суспензии, когда доза кортикостероида в композиции и суспензии является примерно одинаковой.
14. Применение по п.1, в котором значение AUCinf, полученное для композиции, содержащей кортикостероид, по меньшей мере в 1,5 раза больше значения AUCinf, полученного для композиции на основе суспензии, когда доза кортикостероида в композиции примерно в 2 раза меньше дозы в суспензии.
15. Применение по п.1, в котором композиция обеспечивает достижение значения AUC0-8 час (пг·ч/мл), равного 2000-3000, на основе данных, ненормализованных в отношении дозы кортикостероида.
16. Применение по любому из пп.1 или 3-6, в котором кортикостероид является будезонидом.
17. Применение по любому из пп.1 или 3-6, в котором кортикостероид выбран из группы, состоящей из дипропионата беклометазона, монопропионата беклометазона, будезонида, циклезонида, дезизобутирилциклезонида, флунизолида, пропионата флутиказона, фуроата флутиказона, фуроата мометазона, энбутата икометазона, 21-пивалата тиксокортола и ацетонида триамцинолона.
18. Применение по любому из пп.1 или 3-6, в котором композицию вводят распылителем, выбранным из группы, состоящей из пневматического струйного распылителя, ультразвукового распылителя, электронного распылителя, распылителя с вибрирующей мембраной, распылителя с вибрирующим ситом, распылителя с вибрирующей пластиной, распылителя, включающего вибратор и водную камеру, и распылителя с несколькими соплами.
19. Способ получения композиции, содержащей кортикостероид, который включает смешивание с большим сдвигающим усилием кортикостероида, SAE-CD и водного жидкого носителя, при этом SAE-CD присутствует в количестве, достаточном для растворения кортикостероида.
20. Способ по п.19, в котором смешивание с большим сдвигающим усилием выполняют при помощи ультразвукового устройства, градуированных шприцев, смесителя/гомогенизатора, роторно-статорного смесителя или смесителя с пилообразными зубьями.
RU2011104059/15A 2006-06-30 2011-02-04 Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид RU2011104059A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/479,979 US20070020299A1 (en) 2003-12-31 2006-06-30 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US11/479,979 2006-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2009102994/15A Division RU2009102994A (ru) 2006-06-30 2006-12-19 Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид

Publications (1)

Publication Number Publication Date
RU2011104059A true RU2011104059A (ru) 2012-08-10

Family

ID=38894876

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2009102994/15A RU2009102994A (ru) 2006-06-30 2006-12-19 Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид
RU2011104059/15A RU2011104059A (ru) 2006-06-30 2011-02-04 Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2009102994/15A RU2009102994A (ru) 2006-06-30 2006-12-19 Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид

Country Status (13)

Country Link
US (9) US20070020299A1 (ru)
EP (1) EP2043599A4 (ru)
JP (4) JP2009542649A (ru)
KR (3) KR101691222B1 (ru)
CN (2) CN102319231A (ru)
AU (1) AU2006345712A1 (ru)
BR (1) BRPI0621773A2 (ru)
CA (2) CA2656318A1 (ru)
IL (1) IL196185A0 (ru)
MX (1) MX2009000065A (ru)
NZ (1) NZ597354A (ru)
RU (2) RU2009102994A (ru)
WO (3) WO2008005053A1 (ru)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7650004B2 (en) * 2001-11-15 2010-01-19 Starkey Laboratories, Inc. Hearing aids and methods and apparatus for audio fitting thereof
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
US7986790B2 (en) * 2006-03-14 2011-07-26 Starkey Laboratories, Inc. System for evaluating hearing assistance device settings using detected sound environment
US8681999B2 (en) * 2006-10-23 2014-03-25 Starkey Laboratories, Inc. Entrainment avoidance with an auto regressive filter
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
ES2781949T3 (es) 2007-11-13 2020-09-09 Meritage Pharma Inc Composiciones para el tratamiento de la inflamación gastrointestinal
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US8718288B2 (en) * 2007-12-14 2014-05-06 Starkey Laboratories, Inc. System for customizing hearing assistance devices
US20110082150A1 (en) * 2008-02-11 2011-04-07 Robert Owen Cook Headache pre-emption by dihydroergotamine treatment during headache Precursor events
US8571244B2 (en) * 2008-03-25 2013-10-29 Starkey Laboratories, Inc. Apparatus and method for dynamic detection and attenuation of periodic acoustic feedback
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US20110224232A1 (en) * 2008-05-06 2011-09-15 Board Of Regents, The University Of Texas System Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
EP2282725A4 (en) * 2008-06-05 2012-07-04 Cpex Pharmaceuticals Inc NASAL FORMULATIONS OF INSULIN
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
US8668901B2 (en) * 2009-02-04 2014-03-11 Activaero Gmbh Research & Development Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
US8834848B2 (en) * 2009-02-04 2014-09-16 Activaero Gmbh Research & Development Flow and volume regulated inhalation for treatment of severe oral corticosteroid-dependent asthma
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US8359283B2 (en) * 2009-08-31 2013-01-22 Starkey Laboratories, Inc. Genetic algorithms with robust rank estimation for hearing assistance devices
EP2473161B1 (en) 2009-08-31 2017-05-17 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US20120208857A1 (en) * 2009-10-13 2012-08-16 Burak Eric S Pharmaceutical Compositions
US9729976B2 (en) * 2009-12-22 2017-08-08 Starkey Laboratories, Inc. Acoustic feedback event monitoring system for hearing assistance devices
IN2012DN04858A (ru) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
WO2011135585A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Aqueous pharmaceutical solution of ciclesonide
AU2011305567A1 (en) * 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
WO2012066086A1 (en) * 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
EP2749284A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and carmoterol
EP2723735A4 (en) 2011-06-23 2015-02-18 Map Pharmaceuticals Inc NOVEL ANALOGUES OF FLUORO-ERGOLINE
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
SG11201403433PA (en) * 2011-12-21 2014-07-30 Map Pharmaceuticals Inc Novel neuromodulatory compounds
WO2013112605A2 (en) 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
JP2015508846A (ja) 2012-02-28 2015-03-23 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
HUE056838T2 (hu) 2012-08-21 2022-04-28 Sage Therapeutics Inc Allopregnanolon makacs epileptikus állapot kezelésére
SG11201503089WA (en) 2012-10-22 2015-05-28 Cydex Pharmaceuticals Inc Alkylated cyclodextrin compositions and processes for preparing and using the same
WO2014100351A2 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
EP2938339B1 (en) * 2012-12-27 2020-08-19 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
CN105188758A (zh) * 2013-03-15 2015-12-23 梅迪奇斯医药公司 氟尼缩松的局部组合物及治疗方法
ES2746951T3 (es) * 2013-03-29 2020-03-09 Ocean Farma S R L Suspensión oral para tratar esofagitis eosinofílica
US9393177B2 (en) 2013-08-20 2016-07-19 Anutra Medical, Inc. Cassette assembly for syringe fill system
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
EP4122469A1 (en) * 2014-03-28 2023-01-25 Paul Maes Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
WO2015150968A2 (en) * 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Lyophilized pharmaceutical composition of fc-peptide fusion protein
AU2015252908B2 (en) * 2014-05-01 2017-12-07 Integral Biosystems Llc Membrane-adherent self-assembled systems for treatment of ocular disorders
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
HUE063851T2 (hu) 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
KR20170129126A (ko) * 2015-02-13 2017-11-24 벤더르빌트 유니버시티 밀리논 조성물 및 이를 투여하기 위한 방법
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
IL302519A (en) 2015-05-07 2023-07-01 Novimmune Sa Methods and preparations for diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers
JP2018521000A (ja) 2015-05-29 2018-08-02 シドネキシス，インク． Ｄ２ｏで安定化された医薬製剤
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
CN104971039B (zh) * 2015-07-07 2018-04-17 上海通用药业股份有限公司 一种含溶液型醋酸曲安奈德的医用产品
KR20180101438A (ko) 2016-01-08 2018-09-12 테론 파마슈티칼즈, 인크. 7-아조니아바이사이클로[2.2.1]헵탄 유도체의 건조 분말 흡입기 조성물
US11291672B2 (en) 2016-01-12 2022-04-05 Grace Therapeutics Inc. Betamethasone oral spray formulation and method of use to treat ataxia
WO2017123933A1 (en) 2016-01-15 2017-07-20 Massachusetts Eye And Ear Infirmary Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
IL300422A (en) 2016-03-08 2023-04-01 Sage Therapeutics Inc Neuroactive steroids, preparations and their uses
CN106070189A (zh) * 2016-06-17 2016-11-09 京博农化科技股份有限公司 一种展膜油剂成膜助剂
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
EA201990606A1 (ru) * 2016-11-16 2019-10-31 Распыляемый тиотропий
US20200206166A1 (en) 2017-07-20 2020-07-02 Centrexion Therapeutics Corporation Methods and compositions for treatment of pain using capsaicin
US11119094B2 (en) * 2017-09-27 2021-09-14 Cd Diagnostics, Inc. Aqueous citrate-buffered metal solutions
WO2019100362A1 (en) * 2017-11-27 2019-05-31 Wise Ally Holdings Ltd Vaporizer system
US10583081B1 (en) * 2017-11-27 2020-03-10 Richard A. Myers Apparatus and formulation for treating mouth ulcers
WO2020247376A1 (en) * 2019-06-03 2020-12-10 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
US11572295B1 (en) * 2019-06-11 2023-02-07 Swamp Fox Innovations, LLC Compositions and methods for reduction of free chlorine and related odor
CN110551226B (zh) * 2019-07-30 2021-06-08 大连理工大学 一种亲/疏水性可控转换的叔胺型含氮聚糖衍生物及其制备方法和应用
CN110559675A (zh) * 2019-09-20 2019-12-13 新疆天业（集团）有限公司 糊树脂干燥生产控制方法
IT201900022881A1 (it) * 2019-12-03 2021-06-03 Ntc Srl Budesonide per uso oftalmico in un metodo di trattamento dell’occhio
CN114746098A (zh) * 2019-12-03 2022-07-12 Ntc有限公司 用于眼科的包含布地奈德的组合物
US20210205223A1 (en) * 2020-01-04 2021-07-08 Cai Gu Huang Propellant-free formulation for inhalation
US20210275449A1 (en) * 2020-03-01 2021-09-09 Cai Gu Huang Inhalable Formulation of a Solution Containing Glycopyrronium Bromide
WO2021252577A1 (en) * 2020-06-09 2021-12-16 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
CN115884756A (zh) * 2020-06-09 2023-03-31 广州谷森制药有限公司 含有格隆溴铵和马来酸茚达特罗的药物制剂
CN115835885A (zh) * 2020-06-23 2023-03-21 广州谷森制药有限公司 包含奥达特罗和布地奈德的药物组合物的制备
US20230263725A1 (en) * 2020-07-09 2023-08-24 Beyond Barriers Therapeutics, Inc. Intranasal administration of an antioxidant compound for treating coronavirus infection
US20230285350A1 (en) * 2020-07-15 2023-09-14 Lyotip, Inc. Formulations for tetracaine and lidocaine
WO2022073009A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
GB202107153D0 (en) * 2021-05-19 2021-06-30 UCB Biopharma SRL Method for filling vials containing liquid drug products
US11904046B1 (en) * 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations
CN116693704B (zh) * 2023-06-26 2024-08-23 郑州轻工业大学 一种基于烟草废弃物的纤维素纳米晶的制备方法

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008875A (en) * 1960-01-08 1961-11-14 Upjohn Co Neomycin and mirystyl-gamma-picolinium halide compositions
NL289785A (ru) * 1962-11-29
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
HU190356B (en) * 1981-10-27 1986-08-28 Richter Gedeon Vegyeszeti Termekek Gyara Rt,Hu Process for preparing steroid-gamma-cyclodextrin inclusion complexes with high water-solubility
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58225010A (ja) 1982-06-25 1983-12-27 Dai Ichi Seiyaku Co Ltd コルチコステロイド類外用製剤
SE8305864D0 (sv) 1983-10-25 1983-10-25 L E Medical Ogondroppar
JPS61221120A (ja) 1985-03-28 1986-10-01 Nitto Electric Ind Co Ltd 外用医薬部材
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
EP0381747A4 (en) 1988-08-15 1991-09-11 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
EP0491812A4 (en) 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
SE8903219D0 (sv) 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1991013100A1 (en) 1990-03-02 1991-09-05 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
JPH04198180A (ja) 1990-11-28 1992-07-17 Eezai Kagaku Kk ベンジルフタラゾン誘導体の製造方法
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
DE4207922A1 (de) 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5840881A (en) 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US5510339A (en) 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
US5525623A (en) 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
AU6428894A (en) * 1993-03-26 1994-10-24 Franciscus W.H.M. Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
BE1007402A5 (nl) * 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
EE9700136A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Paratüroidhormooni PTH sisaldav ravimpreparaat inhaleerimiseks
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5840713A (en) 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
US5576645A (en) 1995-06-05 1996-11-19 Hughes Aircraft Company Sample and hold flip-flop for CMOS logic
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US5935941A (en) * 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
WO1997046243A1 (en) 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
AU4717997A (en) 1996-10-28 1998-05-22 Farmarc Nederland Bv Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
SE9604486D0 (sv) * 1996-12-05 1996-12-05 Astra Ab Novel formulation
US6071910A (en) 1996-12-05 2000-06-06 Mayo Foundation For Medical Education And Research Use of agents to treat eosinophil-associated pathologies
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
SE9701956D0 (sv) * 1997-05-23 1997-05-23 Astra Ab New composition of matter
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE69834154T2 (de) * 1997-07-01 2007-01-25 Pfizer Products Inc., Groton Verfahren zur Herstellung von einem Cyclodextrin
AU2006200277B2 (en) 1997-09-29 2008-04-10 Novartis Ag Perforated microparticles and methods of use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
JP2003522207A (ja) 1998-02-23 2003-07-22 サイクロプス・イーエイチエフ 高エネルギーシクロデキストリン複合体
RU2157214C2 (ru) 1998-04-16 2000-10-10 Государственный научный центр лекарственных средств Противовоспалительное и антимикробное лекарственное средство для местного применения
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
US20020198174A1 (en) 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
US6297227B1 (en) * 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
MA25590A1 (fr) 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
AU772204B2 (en) 1999-01-21 2004-04-22 Bristol-Myers Squibb Company Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
FR2789685B1 (fr) * 1999-02-15 2001-05-04 Univ Lille Sciences Tech Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s)
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US6962151B1 (en) * 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US6479467B1 (en) * 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
RU2180217C2 (ru) 2000-03-21 2002-03-10 Закрытое акционерное общество "Пульмомед" Стабильный водный раствор противовоспалительного действия, содержащий будесонид
WO2001072338A1 (en) 2000-03-28 2001-10-04 Farmarc Nederland Bv Alprazolam inclusion complexes and pharmaceutical compositions thereof
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20020025946A1 (en) * 2000-05-11 2002-02-28 Buchanan Charles M. Acylated cyclodextrin: guest molecule inclusion complexes
GB0016876D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
MXPA03004241A (es) 2000-11-15 2004-12-03 Chandavarkar Mohan A Preparaciones farmaceuticas que comprenden corticosteroides y agentes antiinfecciosos.
ES2266310T3 (es) * 2000-11-24 2007-03-01 Breath Limited Esterizacion de suspensiones de glucocorticosteriodes.
WO2002055562A2 (en) * 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
ATE325135T1 (de) * 2001-02-14 2006-06-15 Akzo Nobel Nv 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN
US8137699B2 (en) * 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030118512A1 (en) 2001-10-30 2003-06-26 Shen William W. Volatilization of a drug from an inclusion complex
US20030091513A1 (en) * 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
CA2463687A1 (en) 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
CA2464250C (en) 2001-10-24 2008-08-05 Frank-Christophe Lintz Kit for the preparation of a pharmaceutical composition
KR20030041577A (ko) 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
AU2003217623A1 (en) 2002-02-20 2003-09-09 Sepracor Inc. Amino acid and peptide-modified forms of glucocorticoids
US7128928B2 (en) 2002-02-22 2006-10-31 Pharmacia Corporation Ophthalmic formulation with novel gum composition
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
CN1232539C (zh) 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7029657B2 (en) 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
EP2319584A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium
US20040045546A1 (en) * 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
AU2003275329B2 (en) * 2002-09-13 2008-04-03 Cydex Pharmaceuticals, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003295344B2 (en) * 2002-10-09 2008-01-31 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
WO2004069280A1 (en) * 2003-02-06 2004-08-19 Cipla Ltd Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent
MXPA05008649A (es) 2003-02-14 2005-11-23 Combinatorx Inc Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
EP1596822A2 (en) 2003-02-17 2005-11-23 Sun Pharmaceuticals Industries Ltd. A low dose corticosteroid composition
BRPI0407583A (pt) 2003-02-21 2006-02-14 Sun Pharmaceutical Ind Ltd solução oftálmica lìmpida e estável
US20040204394A1 (en) * 2003-04-11 2004-10-14 Aderis Pharmaceuticals, Inc. Triptolide analogues
CA2532874A1 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
WO2005027853A2 (en) 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
US20050112199A1 (en) 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
EP1678211A4 (en) * 2003-10-31 2008-04-02 Univ Kansas SULFOALKYL ETHER-ALKYL ETHER CYCLODEXTRINS DERIVATIVES
GB0329918D0 (en) 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
WO2005065435A2 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
EP2708225B1 (en) * 2004-04-23 2018-12-26 CyDex Pharmaceuticals, Inc. DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US6969706B1 (en) 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
US20060045850A1 (en) 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
GB0422413D0 (en) * 2004-10-08 2004-11-10 Breath Ltd High efficiency nebulisation
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060105045A1 (en) 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
SI2522365T1 (sl) * 2004-11-24 2017-02-28 Meda Pharmaceuticals Inc. Sestavki, ki obsegajo azelastin, in postopki njihove uporabe
US20060120967A1 (en) 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils
CN101180038A (zh) 2005-03-23 2008-05-14 伊兰制药国际有限公司 纳米颗粒皮质类固醇和抗组胺药制剂
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
WO2007054974A2 (en) 2005-09-28 2007-05-18 Arch Pharmalab Limited A green chemistry process for the preparation of pregnadiene esters
EP1971346A2 (en) 2005-12-20 2008-09-24 Tika Läkemedel AB Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070160542A1 (en) 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197487A1 (en) 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an increased lung deposition
US20070185066A1 (en) 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178050A1 (en) 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070249572A1 (en) 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
EP1988878A2 (en) 2006-02-15 2008-11-12 Tika Läkemedel AB Sterilization of corticosteroids with reduced mass loss
EP1894559A1 (en) 2006-09-01 2008-03-05 PARI Pharma GmbH Means to solubilise steroids for inhalation
CN101199855A (zh) 2006-12-13 2008-06-18 天津药业研究院有限公司 皮质激素包合物水溶液及其应用
CN101273993A (zh) 2007-03-27 2008-10-01 北京亚欣保诚医药科技有限公司 糠酸莫米松溶液型液体制剂
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
CA2707158A1 (en) 2007-11-28 2009-06-04 Revision Therapeutics, Inc. Modulators of ocular oxidative stress
UY33367A (es) 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
WO2015109201A1 (en) 2014-01-17 2015-07-23 Nephron Pharmaceuticals Corporation Budesonide cyclodextrin formulation

Also Published As

Publication number Publication date
US20070202054A1 (en) 2007-08-30
JP2014159467A (ja) 2014-09-04
WO2008005819A3 (en) 2008-10-23
US20110123518A1 (en) 2011-05-26
US20130059826A1 (en) 2013-03-07
US10159752B2 (en) 2018-12-25
IL196185A0 (en) 2009-09-22
US20190192684A1 (en) 2019-06-27
JP6409090B2 (ja) 2018-10-17
US9827324B2 (en) 2017-11-28
CA2656318A1 (en) 2008-01-10
MX2009000065A (es) 2009-03-06
WO2008005053A1 (en) 2008-01-10
NZ597354A (en) 2013-08-30
US20110251157A1 (en) 2011-10-13
WO2008005802A2 (en) 2008-01-10
US20130303498A1 (en) 2013-11-14
US10207008B2 (en) 2019-02-19
JP2017149765A (ja) 2017-08-31
CA2728386C (en) 2016-06-07
US20180154015A1 (en) 2018-06-07
BRPI0621773A2 (pt) 2011-12-20
US20190105404A1 (en) 2019-04-11
CN101636144A (zh) 2010-01-27
US10799599B2 (en) 2020-10-13
RU2009102994A (ru) 2010-08-10
KR101807726B1 (ko) 2017-12-11
CN102319231A (zh) 2012-01-18
KR20160077228A (ko) 2016-07-01
KR20150043563A (ko) 2015-04-22
KR20090057174A (ko) 2009-06-04
KR101691222B1 (ko) 2016-12-29
CA2728386A1 (en) 2008-12-31
EP2043599A1 (en) 2009-04-08
AU2006345712A1 (en) 2008-01-10
US20070020299A1 (en) 2007-01-25
WO2008005819A2 (en) 2008-01-10
WO2008005802A3 (en) 2009-04-09
EP2043599A4 (en) 2011-06-29
JP2009542649A (ja) 2009-12-03
JP2019006818A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
RU2011104059A (ru) Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид
JP2009542649A5 (ru)
CN1097455C (zh) 用于制造无推进剂气溶胶的新颖含水药物制剂
JP6140321B2 (ja) 鼻および眼へのコルチコステロイド水溶液送達
CN1976679B (zh) 含有磺基烷基醚环糊精以及皮质甾类的吸入制剂
TW537903B (en) New stable pharmaceutical preparation for producing propellant gas-free aerosols
ES2909080T3 (es) Formulación de DPI que contiene sulfoalquil éter ciclodextrina
US20020137764A1 (en) Inhalable formulation of a solution containing a tiotropium salt
EP1894559A1 (en) Means to solubilise steroids for inhalation
US20120067343A1 (en) Aerosol Composition for Administering Drugs
JP2006517981A (ja) 低用量コルチコステロイド組成物
EP4274577A1 (en) Inhalable imatinib formulation
JP2013227351A (ja) コルチコステロイド製剤を投与する方法
US20220339414A1 (en) Nasal and ophthalmic delivery of aqueous corticosteroid solutions
CN116897045A (zh) 可吸入伊马替尼制剂
CN1750810A (zh) 低剂量皮质类固醇组合物
MXPA99005660A (en) New aqueous medicament preparations for the production of propellent gas-free aerosols
RU2008129648A (ru) Способ введения кортикостероидов